ABEO stock icon

Abeona Therapeutics
ABEO

$4.57
1.74%
 

About: Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Employees: 84

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 9 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,132% more call options, than puts

Call options by funds: $5.18M | Put options by funds: $421K

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

28% more capital invested

Capital invested by funds: $82.1M [Q4 2023] → $105M (+$22.6M) [Q1 2024]

17% more funds holding

Funds holding: 48 [Q4 2023] → 56 (+8) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

13.36% less ownership

Funds ownership: 66.17% [Q4 2023] → 52.81% (-13.36%) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$21
360%
upside
Avg. target
$26
469%
upside
High target
$36
688%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Stifel
Dae Gon Ha
360%upside
$21
Buy
Initiated
30 May 2024
Cantor Fitzgerald
Kristen Kluska
360%upside
$21
Overweight
Maintained
16 May 2024
Cantor Fitzgerald
Kristen Kluska
688%upside
$36
Overweight
Reiterated
23 Apr 2024

Financial journalist opinion

Based on 9 articles about ABEO published over the past 30 days